TY - JOUR T1 - Clinical Outcome of the Patients With Brain Metastasis from Soft Tissue Sarcomas JF - Anticancer Research JO - Anticancer Res SP - 1027 LP - 1034 DO - 10.21873/anticanres.14858 VL - 41 IS - 2 AU - TOSHIYUKI TAKEMORI AU - TERUYA KAWAMOTO AU - MASAYUKI MORISHITA AU - HITOMI HARA AU - NAOMASA FUKASE AU - YOHEI KAWAKAMI AU - SHUICHI FUJIWARA AU - KAZUMICHI KITAYAMA AU - SHUNSUKE YAHIRO AU - TOMOHIRO MIYAMOTO AU - TAKUYA FUJIMOTO AU - IKUO FUJITA AU - YUTAKA MIFUNE AU - YUICHI HOSHINO AU - KENICHIRO KAKUTANI AU - TOMOYUKI MATSUMOTO AU - TAKEHIKO MATSUSHITA AU - TAKAHIRO NIIKURA AU - RYOSUKE KURODA AU - TOSHIHIRO AKISUE Y1 - 2021/02/01 UR - http://ar.iiarjournals.org/content/41/2/1027.abstract N2 - Background/Aim: This study aimed to evaluate the association of clinical characteristics with treatment outcomes to ascertain the appropriate treatment options for soft tissue sarcomas (STS) patients with brain metastasis (BM). Patients and Methods: Medical records of STS patients with BM who were treated in our institutions were retrospectively reviewed, and analyzed to identify the factors associated with post-BM survival. Results: Among the 509 STS patients, BM occurred in five patients (0.98%). The median survival after BM was 1.5 months. Histological subtypes of the primary lesions in the five BM patients were: two synovial sarcomas, one myxoid liposarcoma, one alveolar soft part sarcoma, and one rhabdomyosarcoma. Among the five BM patients, the post-BM survival of two patients, who underwent surgery and postoperative radiotherapy, was longer than that of the other patients (p<0.01). Conclusion: Combined surgery and postoperative radiotherapy effectively managed symptoms and prolonged survival in STS patients with BM. ER -